Hpv Immunisation Programme And The New Zealand Public Health And Disability Act 2000 Essay

This year alone approximately 12,360 documented new cases of cervical cancer in the United States and 4,020 deaths according to National Cancer Institute (“Cervical Cancer”, 2014). Cervical cancer is a slow growing cancer that grows in the tissues of the cervix (an organ that connects the uterus and vagina). The disease is predominantly caused by the human papillomavirus infection (HPV). According to the Center for Disease Control and Prevention, the HPV virus is so common that nearly all sexually active women and men get it at some point in their lives. Many types of HPV exist, some causing genital warts and potentially cervical cancer. Individuals can get HPV by having unprotected genital to genital touching, oral, vaginal, or anal sex. Anyone who is sexually active can get HPV, and can develop symptoms years after they had sex with someone who is infected, making it difficult to know when they first became infected.

Throughout the world, HPV is also very prevalent. Cervical cancer from HPV is the second most common cancer in women living in underdeveloped countries (WHO, 2016). Many of these underdeveloped and lower income countries do have access now to the common forms of the HPV vaccine. In 2008, more than 500,000 new cases of HPV were reported worldwide (WHO, 2016). The prevalence of cases throughout the world is about 79 million reported cases (WHO, 2016).

In addition, the immune system of most women will usually suppress or eliminate HPVs. This is very important because only an ongoing persistent infection has the potential to lead to cervical cancer (HPV). Eleven thousand cases of this kind of cancer were confirmed in 2007 in the United States; the amount undiagnosed is still unclear but believed to be in the tens of thousands. But to give some perspective of the problem you need to understand its effects on a global level. On the world wide scale cervical cancer strikes nearly half a million women each year, claiming more than a quarter of a million lives. “High risk” HPV types 16 and 18 are implicated in Seventy percent of cervical cancers and are hence selected for vaccine targets (The HPV).

Human papillomavirus is currently affecting the entire US population without discrimination. To mitigate this, the Advisory Committee on Immunization Practices (ACIP) recommended that adolescent girls be required to vaccinate at age 11 – 12 while boys were optional (Kepka et al., 2016). Today, adolescent boys are required to vaccinate too. The focus of this research is about adolescent boys age 12 – 15 in the United States (US). However, the study is not focused on assessing the population at risk. Instead, the focus will be on the state and territory immunization programs that are responsible for meeting the Healthy People 2020 goals for HPV vaccination in males. The sample size will be extracted from the population.

Prophylactic vaccination against high risk human papilloma virus 16 and 18 represents an exciting means of protection against HPV related malignancy. However, this strategy alone, even if there is a level of cross protection against other oncogenic viruses, cannot completely prevent cervical cancer. In some countries cervical screening programs have reduced the incidence of invasive cervical cancer by up to 80 percent although this decline has now reached a plateau with current cancers occurring in patients who have failed to attend for screening or where the sensitivity of the tests have proved inadequate. Cervical screening is inevitably associated with significant anxiety for the many women who require investigation and treatment following abnormal cervical cytology. However, it is vitally important to stress the need for continued cervical screening to complement vaccination in order to optimize prevention in vaccines and prevent cervical cancer in older women where the value of vaccination is currently unclear. It is likely that vaccination will ultimately change the natural history of HPV disease by reducing the influence of the highly oncogenic types HPV 16 and 18. In the long term this is likely to lead to an increase in recommended screening intervals. HPV vaccination may also reduce

There are many reasons that this vaccine could be beneficial, not only to our society, but to many of the underdeveloped nations of the world in which HPV and cervical cancer are still considered to be an epidemic (MacDonald). It could save the young women who get the vaccine from the future trouble of dealing with a highly invasive cancer, as well as protect them from the embarrassment that comes with contracting a venereal disease. However, the controversy of this topic is not in whether the vaccine is a benefit to women’s health, which many, including the FDA and the Centers for Disease Control, believe that it is; but in the debate over whether it is the parents’ right, not the states’, to choose what is best for their child. The question of mandatory vaccination raises medical, moral and legal issues that are not easily reconcilable (Lovinger). Many parents are opposed to the mandating of this vaccine for three reasons. First, HPV is not spread by casual contact, as are the other diseases that children are vaccinated against for the safety of the classrooms. Second, the vaccine has only been approved for a short while, thus not all of the side effects and long term effects are known. Last, parents are afraid that by getting their child vaccinated against a sexually transmitted disease they will be encouraging promiscuity. Gardasil would become the first vaccine mandated for school-aged children that targets a

Not a very strong case could be made for requiring that schoolgirls ages twelve and upward be required to be vaccinated against HPV. The vaccine only protects against two cancer-causing strains of HPV, so those who are vaccinated must still be regularly tested for precancerous changes in cervical cells, with a regular pap smear exam. Because of this many parents may object to exposing their children to the risks of side effects that come along with the vaccine. The HPV virus is spread by sexual contact, not airborne or casual interaction, so schools shouldn’t be able to mandate that the vaccine be a requirement for school girls.

Human papillomavirus (HPV) is a sexually-transmitted infection (STI) which includes over forty strains, several of which are the cause of 70% of cervical cancer cases (Thomas, 2008). The Food and Drug Administration licensed the vaccine, Gardasil, produced by the pharmaceutical company, Merck, in June 2006 as a safe and effective means for preventing cervical cancer caused by HPV (Thomas, 2008). The vaccine can be administered in young girls starting at the age of 9 years old and has been recommended for all girls and women between the ages of 13 and 26 years old with the vaccine being most effective prior to beginning sexual activity (Thomas, 2008). Compulsory vaccination mandates require vaccination of particular individuals and have been proposed as a means to achieving profound levels of HPV immunization throughout female adolescent populations within the United States (Balog, 2009). This paper will focus on a discussion of the current debate surrounding compulsory HPV vaccination mandates, the ethical principles underlying the issue, and how this issue relates to the practice of professional nursing.

Many believed or thought that by receiving the HPV vaccination, girls and boys are more likely to engage in sexually risky behavior than girls and boys who did not receive the vaccine. One must ask themselves, does this vaccine actually cause promiscuity among those who have received it? A study was conducted in Ontario to test the effect that the HPV vaccine had on sexual behavior among adolescent girls. The study was conducted on girls in 8th Grade who before (2005-2007) and after (2007-2009) the girls received the vaccine. The results of the study concluded that there was no evidence that the HPV vaccine had any effect on sexual behavior of adolescent girls (Smith, L. M., Kaufman, J. S., Strumpf, E. C., & Lévesque, L. E.). These results suggest that concerns over increased promiscuity following HPV vaccination are unwarranted and should not deter from vaccinating at a young

Schmidt and Parsons investigated the trends of HPV vaccination, interests, and reasons for non-vaccination in young adult women. Results of testing showed that women who had received one or more doses of the vaccine were more likely to be between the ages of 18-21, to be non-hispanic white, to have private health insurance and a usual source of care that has not been delayed, and to have more than a high-school education. Among women 18-26 years of age, the HPV vaccine uptake increased from 11.6% in 2008 to 34.1% in 2012. In 2008 and

The information provided by student Cheryl Gordon pertains to today’s society. The world is getting smaller therefore the risk of contracting an illness increases significantly. Government officials have created many reforms in order to make the necessary and positive changes to have at least the majority of children vaccinated before they enter the school system (Capron, 2015). These precautions have been mandated due to the increase research of the benefits of vaccinations. Children that young are more susceptible of contracting more illnesses. This is why it is important for them to be vaccinated against preventable diseases. One example is the recommendation for routine HPV vaccination for females 11-12 years of age (Klein & Luedtke,

According to the Centers for Disease Control and Prevention (CDC), Human papillomavirus (HPV) infects roughly 20 million individuals in the United States with 6.1 million new cases each year. There is no cure for HPV, only treatment for associated health problems. There are more than 30 strains of HPV that affect more than half of sexually active individuals in their lifetime. Public health risks involve several types of HPV leading to precancerous lesions and causing 70% of cervical cancer. Cervical cancer, the second most common cancer, affects many women globally. In the United States, nearly 10,000 women are diagnosed with cervical cancer annually and 3,700 of those women die. It has been reported by American Cancer Society that with early

Cervical cancer is the leading cause of cancerous death, in women, since 1950. Approximately 200,000 cervical cancer patients die each year in developing countries. Strains like HPV 16 and 18 cause about 70% of cervical cancer in women– one of the top causes of death in the world (WebMD, 2010, p.1). In the Unites States, about 10,000 women acquire the disease and 3,700 die annually Human Papilloma Virus (HPV) is directly associated as a cause of cervical cancer. This virus affects the skin and genital area and, in some cases, it can also infect the throat and mouth. Since the HPV is passed from one person to another through skin-to-skin or sexual contact, sexually active people are more prone to this virus. Merck

As the article dives deeper into the HPV vaccine debate some interesting points were brought up. One thing that was very striking was that cervical cancer kills more than five thousand women in America every year and this number increases in developing countries. It would seem that this is enough of a problem to raise a sense of alarm. Another fact that was given was that HPV is the most common sexually transmitted disease in the United States. A big reason for this is that there are over two hundred strands of HPV and the diversity of this virus helps it to spread. In order for women to be protected against some of the HPV strands she should receive the vaccine before becoming sexually active. This seems to be the push to get girls vaccinated early. Since the average age of first intercourse is under the age of

In the United States, it is one of the eight-most common cancer of women. According to researches, the data shows that Hispanic women are significantly more likely to be diagnosed with cervical cancer than the general population and their median age at diagnosis is 48. In 1998, about 12,800 women were diagnosed in the US and about 4,800 died. Among cancers of the female reproductive tract, it is less common than endometrial cancer and ovarian cancer. The rates of new cases in the United States was 7 per 100,000 women in 2004. Cervical cancer deaths decreased by approximately 74% in the